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unpleasant for families. There 
are more detailed clinical 
descriptions of the distinctive 
facial appearance — flat nasal 
bridge, anteverted nares, wide 
mouth with fleshy lips, long 
filtrum, periorbital fullness, 
epicanthic folds, flat malar 
region, small mandible and 
prominent cheeks — but 
nowadays we have more 
scientifically constrained  
ways of assessing facial 
dysmorphology. For instance, 
three-dimensional face 
images can be captured with 
photogrammetric devices, 
yielding 4,000–20,000 
three- dimensional points 
on the facial surface. Dense 
surface models can then be 
built using specially designed 
computer programs that enable 
researchers to compare very 
fine details of faces within and 
across syndromes and, for 
example, to pinpoint localized 
dysmorphologies of subtle 
facial features in partial deletion 
patients, which the naked clinical 
eye cannot detect. 
Could we say that Williams 
syndrome is the opposite 
of autism? No, that would 
be overly simplistic. For 
instance, featural processing 
is characteristic of both 
Williams syndrome and autism. 
Second, even though people 
with Williams syndrome 
seem extraordinarily friendly, 
their social behaviour is 
as inappropriate as that of 
individuals with autism. Those 
with Williams syndrome cannot 
judge social situations, fail 
to modulate their behaviour 
properly between strangers 
and friends, and tend to stare 
and invade the personal space 
of others. Interestingly, this 
inappropriately friendly Williams 
syndrome behaviour even 
emerges in Japan where such 
immediate intimacy is culturally 
sanctioned. But the Williams 
syndrome brain is indeed 
very different from the autistic 
brain, so cross-syndrome 
comparisons may yield some 
interesting insights into 
gene– brain– cognition–behaviour 
relations.
It all seems so complex: 
shouldn’t researchers simply 
give up or study a syndrome 
caused by only one gene 
instead of 28? Fragile X is no 
simpler to study than Williams 
syndrome. The resulting 
phenotype is very complex  
even when a single gene is 
involved. In my view, Williams 
syndrome constitutes a 
challenging and exciting 
detective story! We still 
need to understand the full 
developmental trajectory from 
infancy onwards, and how 
initially small perturbations can 
have cascading effects on the 
emergent outcome. 
Where can I find out more?
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What is it? Sciagra™ is a 
psychologically self-administered 
drug that acts on grammar and 
vocabulary in scientific papers 
with the aim of improving 
performance, or at least 
convincing the user that it does.
How widespread is its use? 
It’s almost impossible to avoid 
in impact factor zones above 
8. Some disciplines even have 
their own compounds. Psyagra™ 
and Genagra™ are particularly 
dangerous new ‘society’ versions, 
especially potent and unfortunately 
accessible to journalists who have 
to write “It’s the Brain wot does 
it!” or “Scientists produce creature 
that is half human, half grant 
reviewer” stories to tight deadlines.
How do I recognise its use 
by others? The symptoms are 
easy to spot. A user will always 
tell you the impact factor of the 
journal rather than what the 
paper is about. They will display 
an intensity unrelated to the 
importance of the finding and an 
inability to cite anything published 
before 1999. They frequently 
meet rejection of a paper with 
a complaint to the editor, and 
seasoned users may even make 
unsolicited phone calls to editors 
to make their complaint. 
Are there any beneficial side 
effects? In the short term, yes. 
Some people will be impressed by 
your recent performance, or rather 
where you performed, but they 
will expect the same next time, 
so the pressure to keep taking it 
increases.
Who discovered Sciagra™? 
Weak forms have always been 
around but often they were 
limited to occasions when the 
stakes were high or the rivalry 
was personal (for example, Golgi 
versus Cajal). The widespread 
modern compound has only 
emerged since citations and 
impact factors became analogues 
of sales figures and stock values.
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and chisel when I suddenly 
realised there was a dark patch 
of organic matter on a freshly 
removed slab. After some 
cleaning I could identify this as 
a small part of a large claw.”
Late Palaeozoic arthropod 
groups evolved gigantic 
representatives generally 
attributed to a higher 
atmospheric oxygen 
concentration of 35 per cent 
compared with 21 per cent 
today.
Researchers have looked 
at a number of factors that 
may have allowed arthropods 
to reach such sizes, and 
constrained them under present 
conditions. The ability of the 
tracheae to transport oxygen 
to the tissues has been a 
subject of particular interest 
(see Curr. Biol. 17, R969–R971). 
But for this giant sea scorpion, 
the authors believe other 
mechanisms may have been 
involved, perhaps an ‘arms 





There is striking fossil evidence 
that much larger arthropods 
once existed on the planet, 
but a new find pushes the 
boundaries even further. From 
the sediments in a German 
quarry a giant claw has been 
recovered, whose owner was 
a sea scorpion. The size of 
the claw suggests that the 
organism possessing it had a 
body length of up to 2.5 metres.
Simon Braddy, at the 
University of Bristol, 
Markus Poschmann of the 
Archaeological Service in 
Mainz and O. Erik Tetlie at Yale 
University, report the find in 
Biology Letters of the Royal 
Society (published online), 
and suggest it came from the 
largest ever arthropod ever 
recorded.
The claw was found by 
Markus Poschmann in rocks 
390 million years old in a quarry 
near Pruen. “I was loosening 
pieces of rock with a hammer 
Marine giant: Markus Poschmann holds the fossil remains of the claw which has 
led to the projection of a body size for the invertebrate that possessed it of up to 
2.5 metres. (Picture: Simon Braddy.)What are the early signs of use? 
There are no early signs. There 
are only obvious signs common 
to all long-term users. What can 
be spotted is the transition from 
non-user to addict (one episode 
is sufficient for diagnosis). 
For example, an early draft of 
a manuscript may read “We 
replicated and extended a classic 
finding within an established 
theoretical framework…”; a 
later Sciagra™-influenced draft, 
however, would translate this to 
“We show for the first time… and 
provide a novel explanation for…”
Can Sciagra™ be taken as part 
of a career cocktail? Yes. In fact 
prolonged use of Sciagra™ can 
also lead to dependence on impact 
factors and of course the big “H” 
(paradoxically and dangerously 
a little “h”). In fact any h-index 
addicts should be referred to a 
Sciagra™ counsellor as this is 
probably the origin of the problem.
Can its use be prevented? 
It’s up to us really. Scientific 
parenting is important. Do 
supervisors know where their 
students are publishing at night? 
Do supervisors do an adverb 
and superlative check on every 
manuscript — “it’s completely vital 
that they perform this most critical 
of functions.” Do supervisors 
tell their students that it’s OK 
to publish in a journal that has 
“International” in its title? There is 
also talk of an anti-doping service 
which will rewrite Sciagra™ 
influenced papers in plain English. 
What can I say to users? Well, we 
all like a party and have dabbled in 
substances that may not enhance 
our dignity, so righteousness is 
probably not the correct response. 
The most therapeutically effective 
response to Sciagra™ users is: 
“yes, the journal is highly cited, 
but don’t worry, your paper won’t 
change that”. 
Where can I find out more? Call 
me, I know a cheap dealer outside 
the EU.
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